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Release of the malaria merozoite from its host erythrocyte (egress) and invasion of a fresh cell are crucial
steps in the life cycle of the malaria pathogen. Subtilisin-like protease 1 (SUB1) is a parasite serine pro-
tease implicated in both processes. In the most dangerous human malarial species, Plasmodium falcipa-
rum, SUB1 has previously been shown to have several parasite-derived substrates, proteolytic cleavage
of which is important both for egress and maturation of the merozoite surface to enable invasion. Here
we have used molecular modelling, existing knowledge of SUB1 substrates, and recombinant expression
and characterisation of additional Plasmodium SUB1 orthologues, to examine the active site architecture
and substrate speciﬁcity of P. falciparum SUB1 and its orthologues from the two other major human
malaria pathogens Plasmodium vivax and Plasmodium knowlesi, as well as from the rodent malaria species,
Plasmodium berghei. Our results reveal a number of unusual features of the SUB1 substrate binding cleft,
including a requirement to interact with both prime and non-prime side residues of the substrate recog-
nition motif. Cleavage of conserved parasite substrates is mediated by SUB1 in all parasite species exam-
ined, and the importance of this is supported by evidence for species-speciﬁc co-evolution of protease
and substrates. Two peptidyl alpha-ketoamides based on an authentic PfSUB1 substrate inhibit all
SUB1 orthologues examined, with inhibitory potency enhanced by the presence of a carboxyl moiety
designed to introduce prime side interactions with the protease. Our ﬁndings demonstrate that it should
be possible to develop ‘pan-reactive’ drug-like compounds that inhibit SUB1 in all three major human
malaria pathogens, enabling production of broad-spectrum antimalarial drugs targeting SUB1.
 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The continuing appearance and spread of drug-resistant malaria
– in particular alarming reports of resistance to artemisinin-based
drugs (recently reviewed by O’Brien et al., 2011) – emphasises the
need to better understand the biology of the malaria parasite and
to continuously explore new routes to antimalarial drug discovery.
Of the ﬁve Plasmodium spp. known to infect humans, Plasmodium
falciparum is the most virulent and causes by far the greatest mor-
tality. However, Plasmodium vivax is also responsible for extensive
morbidity and can cause severe disease (Price et al., 2007, 2009),
whilst Plasmodium knowlesi has emerged as an agent of potentially
fatal malaria in parts of Malaysia (e.g. William et al., 2011). Work
over the last two decades has demonstrated that proteolytic en-
zymes play crucial roles in the malarial life cycle. In the asexual
blood-stages, responsible for all of the clinical manifestations ofInc. Published by Elsevier Ltd. Op
; fax: +44 (0) 208 816 2730.
ckman).malaria, rupture of schizonts to allow egress of invasive merozoites
can be efﬁciently blocked by the cysteine protease inhibitor E64
(Salmon et al., 2001; Wickham et al., 2003; Soni et al., 2005; Boyle
et al., 2010), implicating at least one cysteine protease. Invasion of
erythrocytes by released merozoites, on the other hand, which in-
volves merozoite surface proteins as well as proteins discharged
from secretory organelles called micronemes and rhoptries, is
insensitive to E64 (Boyle et al., 2010) but can be prevented by ser-
ine protease inhibitors (Hadley et al., 1983). Work to identify the
enzyme(s) involved in egress and invasion revealed that the
Plasmodium genome encodes three proteins belonging to the sub-
tilase superfamily (clan SB, according to MEROPS nomenclature)
(Rawlings et al., 2012), a group of usually secreted serine proteases
that play diverse roles across evolution. Named SUB1, SUB2 and
SUB3, single-copy orthologues of all three are evident in all
Plasmodium genomes examined, including those of P. knowlesi
and P. vivax. Gene disruption experiments in P. falciparum have
shown that SUB3 is not required for asexual blood-stage growth
in vitro (O’Donnell and Blackman, unpublished data). By contrast,en access under CC BY license.
598 C. Withers-Martinez et al. / International Journal for Parasitology 42 (2012) 597–612SUB2 acts as an essential membrane-bound ‘sheddase’ which
cleaves proteins from the surface of the invading merozoite (Harris
et al., 2005). SUB1 is the best studied of the three subtilases, and
previous work from this laboratory has shown that P. falciparum
SUB1 (PfSUB1: PlasmodDB ID PFE0370c, MEROPS ID S08.012) is ex-
pressed late in schizont maturation, accumulating in sub-cellular
organelles of the developing merozoites termed exonemes (Yeoh
et al., 2007). Just prior to egress, PfSUB1 is released into the lumen
of the parasitophorous vacuole (PV), where it proteolytically
cleaves several important parasite proteins. These include mem-
bers of a family of papain-like proteins called the serine rich anti-
gen (SERA) family, and the merozoite surface proteins, MSP1, MSP6
and MSP7 (Yeoh et al., 2007; Koussis et al., 2009). The function of
these processing events is unknown. However, MSP1 is essential
(Combe et al., 2009), and mutations that interfere with its process-
ing are deleterious to parasite growth (Child et al., 2010). There is
also strong evidence that several of the SERA family members play
essential roles (McCoubrie et al., 2007; Putrianti et al., 2010), and it
has been suggested that processing of the SERA proteins may con-
vert them to active proteases (Blackman, 2008). PfSUB1 appears to
be indispensable in the asexual blood-stage P. falciparum life cycle,
and the ﬁnding that selective pharmacological inhibition of PfSUB1
blocks egress and reduces the invasiveness of released merozoites
shows that PfSUB1 is a ‘druggable’ enzyme (Yeoh et al., 2007;
Arastu-Kapur et al., 2008; Koussis et al., 2009). Maturation of
PfSUB1 appears to be dependent on the activity of parasite dipep-
tidyl aminopeptidase 3 (DPAP3), a papain-like cysteine protease
(Arastu-Kapur et al., 2008), and this may be one of the proteases
targeted by E64 in the egress-inhibition experiments referred to
above.
Subtilases are uniﬁed by the characteristic ab-fold of their sin-
gle lobe catalytic domain and the order of the ‘catalytic triad’ res-
idues in their primary sequence. These residues differ between the
two major families of the clan, being Glu-Asp-Ser in the case of the
S53 (sedolisin) family, and Asp-His-Ser in the case of the S8 family
to which the Plasmodium SUB proteases belong (Wlodawer et al.,
2003). Further subdivisions of the S8 family have been made based
on sequence homologies, and the Plasmodium sequences show
most similarity to members of the subtilisin subfamily S8A of pre-
dominantly bacterial enzymes as deﬁned by Siezen and Leunissen
(1997). Subtilisins are generally expressed as zymogens that un-
dergo activation in one or more (usually autocatalytic) processing
steps, releasing a prodomain (PD) to liberate an enzymatically ac-
tive catalytic domain. The substantial homology between the pri-
mary sequence of the PfSUB1 catalytic domain and that of
several bacterial subtilisins, the structures of which have been
determined by X-ray crystallography, allowed us in earlier work
to build a homology model of the PfSUB1 catalytic domain
(Withers-Martinez et al., 2002). This showed that all of the impor-
tant structural features characteristic of subtilases are present in
PfSUB1. These include the eight major a-helix and 11 b-strand ele-
ments that comprise the structurally conserved core of subtilase
catalytic domains, the presence of at least three potential cal-
cium-binding sites, and three predicted intramolecular disulphide
bonds. The substrate binding site within subtilisin catalytic do-
mains forms a prominent surface cleft or groove that allows ex-
tended interactions with at least six substrate residues ﬂanking
the scissile bond (P4 to P20 according to the nomenclature of
Schechter and Berger, 1967). The most important of these interac-
tions are generally within the S4 pocket, a particularly deep inden-
tation within the binding groove, and the S1 pocket which is only
slightly less deep. Our initial analysis of the substrate binding site
within the PfSUB1 homology model (Withers-Martinez et al., 2002)
was made in the light of the only substrate sequence known at that
time, the 213LVSAD ; NIDIS222 motif (scissile bond indicated by adownward-pointing arrow, numbering based on PlasmodDB ID
PFE0370c) within PfSUB1 itself at which autocatalytic cleavage
takes place during protease maturation (Sajid et al., 2000). The
overall hydrophobic character of the predicted PfSUB1 S4 pocket
and the contrasting polar nature of its S1 pocket was in accord with
the substrate sequence, as these pockets accommodate, respec-
tively, the aliphatic P4 Val and hydrophilic P1 Asp residues. The
importance of these sub-site interactions was experimentally ad-
dressed using several derivatives of an N-acetylated peptide sub-
strate, Ac-LVSADNIDIS, revealing that although some ﬂexibility is
tolerated at the P1 position, PfSUB1 cannot cleave substrates con-
taining a P1 Leu residue, whilst replacement of the P4 Val with Ala
inhibits cleavage and replacement with Lys completely ablates
cleavage. The results of this initial analysis, together with peptide
alanine scanning studies and the subsequent mapping of cleavage
sites in a number of authentic endogenous protein substrates of
PfSUB1 (Yeoh et al., 2007; Koussis et al., 2009), enabled us to
assemble a consensus PfSUB1 recognition motif of Ile/Leu/Val/
Thr-Xaa-Gly/Ala-Paa(not Leu) ; Xaa (where Xaa is any amino acid
residue and Paa tends to be a polar residue). We also noticed a
striking tendency for residues with acidic (Glu, Asp) or hydroxyl-
containing (Ser, Thr) side-chains at one or more of the proximal
ﬁve prime side positions in authentic target sequences, an unex-
plained and intriguing observation since no previously-studied
S8A family subtilisin demonstrates strong prime side substrate
preference. Recent use of the consensus motif to perform bioinfor-
matic searches of the predicted P. falciparum proteome for new
PfSUB1 substrates proved productive, enabling ﬁrm identiﬁcation
of the parasite proteins RAP1 and MSRP2 as additional substrates
(Silmon de Monerri et al., 2011). However, the large number of
false positives arising from that screen demonstrated that our cur-
rent understanding of PfSUB1 speciﬁcity is incomplete.
An enhanced understanding of the structural elements impor-
tant for recognition of target sequences would improve algorithms
for prediction of biologically relevant PfSUB1 substrates – essential
for a complete understanding of the function of the enzyme – and
would aid directed design of selective inhibitors. In addition, char-
acterisation of SUB1 orthologues from other Plasmodium spp. of
clinical and/or experimental importance would provide valuable
information on conserved functions as well as on the wider poten-
tial of SUB1 as a drug target. Towards these aims, we report here a
structural investigation of the architecture of the PfSUB1 active site
cleft based on modelling studies. Homology models of PfSUB1
bound to different target sequences now known to be cleaved in
trans in authentic physiological substrates reveal structural fea-
tures required for binding and provide a rational interpretation
of the substrate speciﬁcity found in our previous experiments.
These results are corroborated by molecular dynamics (MD) simu-
lations, which provide further insights into the structural determi-
nants for substrate binding. By comparing the PfSUB1 active site
with that of the P. vivax and P. knowlesi orthologues, as well that
of the widely used experimental rodent malaria model, Plasmo-
dium berghei, we identify unusual features of the SUB1 active site
that may be exploited in the design of SUB1 inhibitors. We show
that there are no substantial differences between the active sites
of the SUB1 orthologues from the human pathogens, whereas the
P. berghei orthologue displays evidence of diversiﬁcation in speci-
ﬁcity and co-evolution of the enzyme and its substrates. We iso-
lated a ‘core’ active domain of recombinant PfSUB1 (rPfSUB1) and
describe the recombinant expression and partial characterisation
of the other SUB1 orthologues under investigation. Finally, we used
the recombinant enzymes to validate some major predictions from
our modelling work, and to present a proof-of-principle that sub-
strate-based inhibitors can be developed that target SUB1 ortho-
logues from all three major human malaria pathogens.
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2.1. Expression and puriﬁcation of recombinant proteins for PfSUB1, P.
vivax SUB1 (PvSUB1), P. knowlesi SUB1 (PkSUB1) and P. berghei SUB1
(PbSUB1)
Recombinant expression and puriﬁcation of PvSUB1, PkSUB1
and PbSUB1 (PlasmoDB ID PVX_097935, PKH_102540 and
PBANKA_110710, respectively) used a protocol adapted from that
previously described for rPfSUB1 (Withers-Martinez et al., 2002).
Brieﬂy, recodonised synthetic genes based on codon usage of Sf9
insect cells and encoding C-terminal six histidine (6-His) tags were
produced by GeneArt (Invitrogen, UK), sub-cloned into the pFast-
Bac1 expression vector (Invitrogen), then used to produce recom-
binant baculovirus using the Bac-to-Bac system (Invitrogen)
according to the manufacturer’s instructions. Large scale protein
production was achieved by infecting 100 ml of Tn5 cells at
2  106 cells/ml in Sf900 II protein-free medium (Invitrogen) con-
taining 0.5 lg/ml of tunicamycin, at a multiplicity of infection of
1–2 in a 500 ml Erlenmeyer ﬂask, and swirling the cells at
85 rpm for 3–4 days at 27 C. Approximately 3 L of accumulated
culture supernatant were clariﬁed, then the secreted recombinant
protein puriﬁed in a two-step procedure using Blue Sepharose
CL-6B (Sigma, UK) and high performance Ni–NTA agarose resin
(Qiagen, UK), as described previously (Withers-Martinez et al.,
2002) except that all elution buffers contained 10 mM 3-[(3cho-
lamidopropyl)-dimethylammonio] propanesulfonate CHAPS and
the Ni–NTA elution buffer contained 250 mM imidazole. If not to
be processed further with chymotrypsin, puriﬁed proteins were
concentrated and buffer-exchanged into 150 mM NaCl, 20 mM
Tris–HCl pH 8.2, using a 10 kDa cut-off Centricon-70 (Millipore,
UK). Protein yields varied from 0.38 mg/L of insect cell culture
for rPfSUB1 to 4 mg/L for rPvSUB1.2.2. Chymotrypsin digestion of recombinant SUB1
Puriﬁed rPfSUB1 in Ni–NTA elution buffer (150 mM NaCl,
20 mM Tris–HCl, pH 8.2, 10 mM CHAPS, 250 mM imidazole) was
supplemented with bovine pancreatic a-chymotrypsin (Sigma cat-
alogue No. C3142, type VII, TLCK-treated) to a ﬁnal concentration
of 5 lg/ml (0.2 U/ml) and incubated at 25 C for 3–4 h. The chy-
motrypsin was inactivated by addition of phenylmethylsulfonyl
ﬂuoride (PMSF) to 2 mM from a 100 mM stock in isopropanol (note
that PfSUB1 is unaffected by PMSF; Withers-Martinez et al., 2002).
The digested protein was ﬁnally puriﬁed by chromatography on a
HiLoad 26/60 Superdex 200 prep-grade column (GE Healthcare,
UK) equilibrated in 20 mM Tris–HCl, 150 mM NaCl, pH 8.2. N-ter-
minal sequencing by Edman degradation of the chymotrypsin-di-
gested rPfSUB1 and other proteins was performed at the Protein
and Nucleic Acid Chemistry Facility (University of Cambridge,
UK). Electrospray mass spectrometry was used to establish the
molecular mass of the chymotrypsin-digested rPfSUB1 as de-
scribed previously (Howell et al., 2003). An identical process was
used for chymotrypsin-treatment of rPvSUB1, rPkSUB1 and
rPbSUB1.2.3. Protease activity and speciﬁcity assays
Unlabelled N-acetylated synthetic peptides and ﬂuorogenic sub-
strate Ac-KITAQ-AMC were purchased from BIOMATIK (USA) or
Pepceuticals (UK). All other ﬂuorogenic peptide substrates used in
this study were produced in-house by labelling both cysteine
side-chains of the following peptideswith 6-iodoacetamido tetram-
ethylrhodamine (6-IATR): Ac-CKITAQDDEESC (SERA4st1F-6R12);Ac-CITAQDDEEC (called SERA4st1F-6R); and Ac-CITAQSDEEC (SER-
A4st1F-6R-S). Labelling, puriﬁcation and use of these peptides was
as described previously (Blackman et al., 2002; Withers-Martinez
et al., 2002; Yeoh et al., 2007). The labelled peptides exhibit low
ﬂuorescence due to non-covalent, concentration-dependent dimer-
ization of the rhodamines. Cleavage anywhere within the peptide
backbone allows dissociation of the rhodamine dimer and conse-
quent ﬂuorescence increase. One unit (1 U) of rPfSUB1 is deﬁned
as the amount of protease that hydrolyses 1 pmol of SERA4st1F-
6R12 in 1 min at a substrate concentration of 0.1 lM in digestion
buffer (25 mM Tris–HCl, pH 8.2, 12 mM CaCl2, 25 mM CHAPS) at
21 C. For kinetic assays, ﬂuorogenic substrate solutions (0.1 lM
in digestion buffer) were supplemented with puriﬁed recombinant
protease (usually1 U/ml), and ﬂuorescence increase continuously
monitored with time at 21 C as described previously (Blackman
et al., 2002) using a Cary Eclipse ﬂuorescence spectrophotometer
(Varian, UK) equipped with a 96-well microplate reader accessory.
Progress curves are displayed as individual reads from a single well
of a kinetic assay; readings taken from triplicate wells in the same
experiments showed no more than 2% variation from the plots
shown at individual time-points. For determination of IC50 (half
maximal inhibitory concentration) values for peptidyl ketoamides
KS-182 and KS-466,wellswere supplemented in triplicatewith var-
ious concentrations of the test compounds, diluted 1:100 from stock
serial dilutions inDMSO, prior to addition of substrate. Initial hydro-
lysis rates were then plotted against inhibitor concentration.
Determination of apparent tight binding inhibition constant Ki(app)
values was performed as described previously (Jean et al., 2003)
using themethod of Nicklin andBarrett (1984),whichuses the slope
of the progress curve in the absence of the inhibitor under test (the
initial velocity vo), and the slope of the curve immediately following
addition of inhibitor (the inhibition velocity vi). A plot of (vo/vi)  1
versus inhibitor concentration has a slope of 1/Ki(app). To conﬁrm the
speciﬁcity of ﬂuorogenic substrate cleavage, samples of the digests
were analysed by reverse-phased (RP)-HPLC on a Vydac
4.6 mm  25 cm C18 RP-HPLC column, using ﬂuorescence to detect
the products of cleavage, as previously described (Blackman et al.,
2002). Where appropriate, pronase (10 lg/ml) was added to diges-
tion reactions to rapidly obtain complete substrate hydrolysis. As
with many ﬂuorogenic peptides, internal quenching and intermo-
lecular dimerization effects were observed with all 6-IATR-labelled
peptides at concentrations >5 lM, so it was not possible experimen-
tally to determine accurate Km values for these substrates. However,
cleavage rates were proportional to substrate concentrations up to
4 lM substrate, indicating that Km values are 4 lM (data not
shown). For determination of cleavage speciﬁcity or relative cleav-
age rates of unlabelled N-acetylated peptides, partially-digested
peptides (2 mM starting concentration) were fractionated by RP-
HPLC eluting at 1 ml/min with either a 0–45% or 4.518% (v/v) gra-
dient of acetonitrile in 0.1% TFA over 25 min. Digestion products
were identiﬁed by electrospray mass spectrometry as described
previously (Withers-Martinez et al., 2002; Yeoh et al., 2007; Child
et al., 2010).
For assessing processing of native SERA5 by rPfSUB1, extracts
containing native SERA5 were produced by hypotonic lysis of ma-
ture P. falciparum 3D7 schizonts into 25 mM HEPES, pH 7.4, 12 mM
CaCl2, containing protease inhibitors, as described previously
(Silmon de Monerri et al., 2011). Samples of extract were supple-
mented with either rPfSUB1 (1–10 U/ml), or puriﬁed rPfSUB1 PD
(84 nM ﬁnal concentration, to prevent cleavage by endogenous
PfSUB1) (Jean et al., 2003), or both. Digestion reactions were al-
lowed to proceed at 37 C for up to 2 h. Samples taken at intervals
were examined by Western blot, probing with the SERA5-speciﬁc
monoclonal antibody 24C6.1F1 (Delplace et al., 1985), a kind gift
of Jean-Francois Dubremetz, University of Montpellier 2, France.
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PfSUB1 numbering used in this study refers to the P. falciparum
3D7 sequence (PlasmoDB ID PFE0370c; Supplementary Fig. S1)
which differs from the P. falciparum T9/96 sequence (GenBank
AJ002233; Blackman et al., 1998) by a deletion of two Ser residues
in a polyserine stretch in the PD region. This makes the 3D7 se-
quence 688 residues in length, two residues shorter than the T9/
96 sequence. Generation of our initial PfSUB1 homology model
was described byWithers-Martinez et al. (2002). To check its valid-
ity and to search for improved models, the Modeller v9.3 suite
(Eswar et al., 2008) was used. To obtain template structures, the
3D7 PfSUB1 sequence was submitted to pGenTHREADER within
the PSIPRED server (http://bioinf.cs.ucl.ac.uk/psipred/). Homology
modelswere generated on the basis of the top seven hits (PDB codes
1BH6, 1DBI, 1GCI, 1THM, 1R0R, 1MEE and 1TO2), using the Model-
ler package with varying numbers of template structures. The best
models were selected on the basis of their DOPE score as calculated
by theModeller package, and on their stereochemical quality as cal-
culated with Procheck (Laskowski et al., 1998). Homology models
for PvSUB1, PkSUB1 and PbSUB1 were then generated based on
the original PfSUB1model, again usingModeller and Procheck (per-
centage amino acid identity with the PfSUB1 catalytic domain are:
PvSUB1: 75%; PkSUB1: 76%; and PbSUB1: 68%; Supplementary
Fig. S1). The root mean square deviation (RMSD) of Ca atoms be-
tween the four resulting models was <0.3 Å. Electrostatic calcula-
tions and all structural ﬁgures were generated with PyMOL (the
PyMOL Molecular Graphics System, Version 1.3, Schrödinger LLC,
Portland, USA, http://www.pymol.org/).
2.5. Modelling PfSUB1–peptide complexes
PfSUB1–peptide complexes were modelled on the basis of the
crystal structures of subtilisin BPN0 and Carlsberg in complex with
Streptomyces subtilisin inhibitor (PDB ID 2SIC; Takeuchi et al.,
1991), eglin (PDB ID 1CSE; Bode et al., 1987; and 1SIB; Heinz
et al., 1991), and chymotrypsin inhibitor 2 (PDB: 2SNI; McPhalen
and James, 1988). The inhibitor-bound subtilisin structures and
the PfSUB1 model were superimposed using Coot (http://www.
biop.ox.ac.uk/coot/; Emsley et al., 2010), and each inhibitor trun-
cated to a 10 residue segment (P5–P50) spanning the enzyme active
site pockets (Supplementary Fig. S2). The template residues were
then replaced with the established PfSUB1 substrate sequence KIT-
AQDDEES (SERA4st1) (Yeoh et al., 2007). The decapeptide was then
manually adjusted in the active site of the PfSUB1 model using
Coot to remove steric clashes. Polar hydrogens were added and
the structure minimised by 500 steps of steepest descent minimi-
sation using the modelling package Quanta 2006 (Accelrys Inc.,
San Diego CA, 2006) together with the CHARMM22 force ﬁeld
(MacKerell, 1998).
2.6. MD simulations
A MD simulation of PfSUB1 bound to the peptide substrate KIT-
AQDDEESwasperformedwith theAmber 11 suite of programs (Case
et al., 2005) together with the ff99SB modiﬁcations (Simmerling
et al., 2002;Hornaket al., 2006) of theCornell et al. (1995) forceﬁeld.
The starting structure for the MD simulation was derived using the
PfSUB1 homology model and modelling the peptide by superposi-
tion of the backbone coordinates of homologue complexes (PDB
codes: 1LW6; Dauter et al., 1991; Radisky and Koshland, 2002;
and 1MEE; Dauter et al., 1991). Missing side chains were built up
by mutation of the corresponding amino acid using tleap from the
Amber 11 package (Case et al., 2005). To avoid terminal charges on
the peptides, theN- and C-terminal residueswere cappedwith acet-
yl (ACE) and N-methylamine (NME) groups, respectively. The sys-tem was neutralised by adding sodium counter-ions and solvated
in a truncated octahedronbox of TIP3P (Jorgensen et al., 1983)water
molecules, forming a solvent shell of at least 11 Å between each face
of the box and the solute. The systemwasminimised by 250 steps of
steepest descent minimisation followed by 250 steps of conjugate
gradient minimisation. The particle mesh Ewald (PME) method
(Cheatham et al., 1995) was used to treat long-range electrostatic
interactions, and bond lengths involving hydrogen atoms con-
strained using the SHAKE algorithm (Ryckaert et al., 1977). The inte-
gration time step for theMD simulationwas 2 fs, with a direct-space
non-bonded cutoff of 9 Å. After minimisation, MD in the canonical
ensemble (NVT) was carried out for 50 ps, during which the system
was heated from 100 to 300 K. Harmonic restraints with force con-
stants of 5 kcal/(mol Å2)were applied to all solute atoms in this step.
Subsequent isothermal isobaric ensemble (NPT)-MDwasperformed
for 50 ps to adjust the solvent density. Finally, the force constants of
the harmonic restraints on the receptor atoms were gradually re-
duced to zero during 250 ps in the NVT ensemble. An additional
50 ps of unconstrained NVT-MD at 300 K with a time constant of
2.0 ps for heat bath coupling were performed to relax the system
without constraints. The production run of the simulation achieved
a length of 50 ns of which snapshots saved at 20 ps intervals were
used for analysis. The ‘ptraj’ module of Amber 11 was used for ana-
lysing the root-mean squareﬂuctuations (RMSF) about themeanpo-
sition of atoms and formation of hydrogen bonds. For RMSF
calculation, overall translational and rotational motions were re-
movedwith respect to theCa-atomsof the PfSUB1 structure. Hydro-
gen bonds were deﬁned by a distance cutoff of 3.2 Å and an angle
cutoff of 120.2.7. Synthesis and puriﬁcation of the peptidic alpha-ketoamides
KS-182 and KS-466, and the peptidic aminoalcohol KS-378
Complete synthetic schemes for synthesis, puriﬁcation and
structural validation of these compounds are provided in Supple-
mentary Data S1.3. Results
3.1. Protease treatment of rPfSUB1 identiﬁes an enzymatically active
core domain with unaltered substrate speciﬁcity
PfSUB1 is synthesised as a 82 kDa precursor zymogen which
undergoes maturation in two sequential processing steps, both
involving truncation from the N-terminus of the protein. In the ﬁrst
step, autocatalytic cleavage occurs at an internal 213LVSAD ; NI-
DIS222 motif to produce a p54 species plus the PD, which remains
in a tight complex with p54 and is a potent inhibitor of the cognate
enzyme, as is common for subtilases (Sajid et al., 2000; Withers-
Martinez et al., 2002). In the second processing step, further
cleavage takes place at Asp249 to produce the p47 form, which
accumulates in exonemes in the parasite. Both processing steps
are recapitulated upon expression of rPfSUB1 in insect cells, but be-
cause the second step only takes place to a limited degree, the pro-
tein is secreted in the form of a heterogeneous mixture of the three
products (Withers-Martinez et al., 2002). Both internal processing
sites lie some distance N-terminal to the start of the PfSUB1 cata-
lytic domain as deﬁned by homology with bacterial subfamily S8A
subtilisins, and therefore both p54 and p47 possess long N-terminal
extensions of unknown function, as well as an unusual 26-residue
C-terminal extension (Withers-Martinez et al., 2002). Previous at-
tempts to obtain enzymatically active rPfSUB1 by expression of
the predicted catalytic domain alone have proved unsuccessful, as
expected (not shown) since the great majority of subtilisin-like en-
zymes absolutely require the PD for correct folding of the catalytic
Fig. 1. Production of an enzymatically active, soluble core domain of recombinant
Plasmodium falciparum subtilisin-like protease 1 (rPfSUB1). (A) Limited chymotryp-
sin-treatment at 25 C of insect cell-derived rPfSUB1 converts it to a relatively
stable 38 kDa core domain (rPfSUB1cat) comprising Ser328 to Tyr671 (see Section
3.1). Note the disappearance of the prodomain in the treated sample, which was
conﬁrmed by Western blot with antibodies speciﬁc for the prodomain (not shown).
(B) Progress curves showing cleavage of ﬂuorogenic substrate SERA4st1F-6R12 by
equivalent masses of rPfSUB1 and rPfSUB1cat. Substrate concentration in this assay
was 0.1 lM, well below the Km for this substrate, which is4 lM. The initial rate of
cleavage mediated by rPfSUB1cat was 9.8-fold faster than that mediated by
untreated rPfSUB1. (C) Time-course showing processing in vitro of P. falciparum-
derived serine rich antigen 5 (SERA5) by rPfSUB1cat. The full-length 120 kDa
SERA5 is rapidly and correctly converted to the expected P76 and P56 forms in the
presence of added rPfSUB1cat. Small amounts of P76 and P56, derived from
endogenous PfSUB1 activity, are present in the starting (0 min) sample, but these
levels do not signiﬁcantly alter with time in samples supplemented with
recombinant prodomain. Some conversion to the terminal SERA5 processing
product P50 is also evident in the rPfSUB1cat-containing samples, presumably due
to the presence in the parasite extracts of the cysteine protease responsible for this
(Yeoh et al., 2007). No processing of SERA5 was observed in the presence of both
rPfSUB1cat and prodomain (not shown).
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structural similarity of the PfSUB1 catalytic domain to the bacterial
subfamily S8A subtilisins, it might be possible to use limited prote-
olytic digestion to convert insect cell-derived p54/p47 to a ‘core’
globular species comprising only the catalytic domain. This would
provide a means to assess whether the catalytic domain of PfSUB1
possesses all of the structural determinants necessary for activity
and substrate speciﬁcity. Puriﬁed rPfSUB1 was subjected to limited
proteolytic digestion with trypsin, pancreatic elastase (data not
shown) or chymotrypsin, then re-puriﬁed. As shown in Fig. 1A,
chymotrypsin treatment efﬁciently and reproducibly converted
the rPfSUB1 to a soluble, homogeneous 38 kDa product (named
rPfSUB1cat), with a concomitant decrease in levels of the associated
inhibitory PD (which was largely degraded by the treatment). Con-
sistentwith this, rPfSUB1cat exhibited substantially increased prote-
olytic activity (Fig. 1B) whilst retaining its substrate speciﬁcity, as
shown by examination of cleavage of both ﬂuorogenic peptide sub-
strates and unlabelled peptides (not shown), plus parasite-derived
SERA5, an authentic protein substrate (Fig. 1C). N-terminal
sequencing of rPfSUB1cat gave homogeneous signals corresponding
to the sequence Ser-Arg-Pro-Gly-Lys in the ﬁrst ﬁve cycles of Edman
degradation, unambiguously assigning its N-terminus as Ser328
(Supplementary Fig. S1). Electrospray mass spectrometric analysis
of rPfSUB1cat in the absence or presence of 100 mM DTT produced
signals atm/z 38,328.3 and 38,333.5, respectively. This corresponds
closely to PfSUB1 sequence extending fromSer328 to Tyr671 (calcu-
lated m/z 38,328.2 if six of the seven Cys residues are engaged in
disulphide bonds, or m/z 38,334.2 in fully reduced form). This se-
quence is only slightly longer than that encompassed by our original
homology model based on bacterial subtilisin catalytic domains
(Phe339-Asn662; Supplementary Fig. S1) (Withers-Martinez et al.,
2002). These results strongly suggest that all the structural features
responsible for PfSUB1 activity and substrate speciﬁcity reside
within the core catalytic domain of the protein.
3.2. Structural analyses of homology models reveal key interactions
which are conserved in the active site cleft of four Plasmodium SUB1
orthologues
The ﬁrst homology model of PfSUB1 was built in our laboratory
almost 10 years ago based on the X-ray crystal structures of the
four most closely homologous bacterial subtilisins available at that
time (Withers-Martinez et al., 2002). Several new subtilisin crystal
structures have subsequently become available, so we generated
new homology models of PfSUB1 based on an extended number
of templates (see Section 2.4 for further details). Encouragingly,
all of the new models showed only marginal differences from the
original PfSUB1 model in the core region, the overall RMSD of the
backbone coordinates between the models deviating only by up
to 0.6 Å, although there was much less deviation within and
around the active site regions (data not shown). Only the loop re-
gions, which are expected to be relatively ﬂexible, show pro-
nounced conformational changes and differ in their modelled
length and composition. We therefore used the original PfSUB1
model for all subsequent analyses.
Fig. 2 shows the PfSUB1 homology model superimposed onto
the catalytic domain structures of the seven bacterial subtilisins
used as templates for our homology modelling. The high degree
of structural conservation within the core of the protein surround-
ing the catalytic Ser is immediately apparent. Variations are seen
only on peripheral loops or strands, where six large insertions
are clearly noticeable in PfSUB1 outside of a 15 Å radius sphere
centred on the catalytic Ser. Despite their absence from homolo-
gous bacterial subtilisins, we have shown previously that individ-
Fig. 2. Structural model of the Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) catalytic domain. Cartoon representation of the PfSUB1 homology model, which
extends from P. falciparum 3D7 PfSUB1 residues 339–662, superimposed onto X-ray crystal structures of seven bacterial subtilisins. These are: subtilisin DY from Bacillus
licheniformis (subtilisin Carlsberg) inhibited by N-benzyloxycarbonyl-Ala-Pro-Phe-chloromethyl ketone (PDB 1BH6, pink); Bacillus sp. Ak.1 subtilisin (1DBI, light blue); Bacillus
lentus subtilisin (1GCI, yellow); Thermoactinomyces vulgaris subtilisin (thermitase) (1THM, orange); Bacillus licheniformis subtilisin inhibited by turkey ovomucoid third
domain (OMTKY3) (1R0R, green); Bacillus mesentericus subtilisin inhibited by eglin-C (1MEE, red); and subtilisin BPN0 from Bacillus amyloliquefaciens (subtilisin Novo)
inhibited by chymotrypsin inhibitor 2) (1TO2, purple). The PfSUB1 homology model is depicted in its see-through molecular envelope (grey). The active site catalytic Ser side
chain is shown as a yellow stick. The six surface ‘loops’ of PfSUB1, which are absent from the bacterial homologues, are clearly visible. The vertical purple bar on the left
indicates a length of 30 Å.
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rPfSUB1 maturation and/or stability of the recombinant protein
in our insect cell expression system, probably due to an impact
on folding (Jean et al., 2005). Of importance for the present study,
however, that analysis provided no experimental evidence that any
of the loops contribute to PfSUB1 substrate speciﬁcity, and indeed
examination of our model is in agreement with that, suggesting
that all of the loops are disposed too far from the active site to im-
pact on substrate binding.
A previous side-by-side comparison of peptide substrates based
on experimentally-conﬁrmed and predicted PfSUB1 cleavage sites
(Supplementary Fig. S3) identiﬁed the most efﬁciently-cleaved
peptide to be an N-acetylated peptide corresponding to a cleavage
site in SERA4, KITAQ ; DDEES (here called SERA4st1) (Koussis et al.,
2009). Fig. 3 shows a structural model of the SERA4st1–PfSUB1
complex. The substrate (shown in non-N-acetylated form) lies in
an extended conformation, the main-chain of the P4–P1 residues
in its N-terminal half forming the upper strand of a two-stranded
antiparallel b-sheet involving PfSUB1 residues Lys465-Gly467 be-
low the groove (Fig. 3A and B). This mode of substrate binding is
typical of subtilisins (Supplementary Fig. S2), and results in the
P1–P4 segment of the substrate being held relatively tightly in
the groove. Other canonical hydrogen-bonding interactions include
between the P3 main chain and Ser492 (which also contributes to
the polar nature of the PfSUB1 S1 pocket via its side-chain – see
below), between the P20 backbone and Asn603, and between thecarbonyl oxygen of the P1 Gln and the oxyanion hole residue
Asn520. Of additional interest is the observation that the side-
chains of two prime side substrate residues, P10 Asp and P30 Glu,
are in a position to interact with the side-chain e-amino group of
Lys465, which forms one end of the lower PfSUB1 b-strand de-
scribed above and which also is a prominent component of the
S2 pocket.
For most S8A subfamily subtilisins, enzyme speciﬁcity is pri-
marily dictated by interactions of the P1–P4 residue side-chains
with the corresponding S1–S4 active site pockets (Siezen and
Leunissen, 1997). Fig. 4 depicts the distribution of the various
PfSUB1 active site pockets and their constituent residues, in asso-
ciation with the SERA4st1 substrate. The enzyme S4 pocket (indi-
cated in pink in Fig. 4A and B) is well deﬁned and partially
buried as it extends into the core of the protein. It is characterised
by a lining of hydrophobic residues, involving PfSUB1 residues
Leu469 which lies at the pocket entrance, plus Met472, Phe491,
Phe493 and Phe500, and is well suited to the aliphatic residues
preferred at the P4 position (Supplementary Fig. S3). The outer
edge of the S4 pocket is formed by Glu495, which may help to sta-
bilize basic residues in the P5 position (see below). In common
with the S8A subfamily bacterial subtilisins, the PfSUB1 S3 pocket
is not well deﬁned, and the side chain of the P3 residue is directed
out towards the solvent with the only signiﬁcant interactions being
the above-mentioned main-chain interactions with Ser492 (Fig. 3).
This likely explains the relative lack of restriction at the substrate
Fig. 3. Structural model of Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) in complex with its substrate reveals a canonical binding mode. (A) Cartoon
representation of PfSUB1 (grey), zoomed on the active site, showing that canonical binding of the SERA4st1 decapeptide substrate KITAQDDEES (P5–P50 , arranged right to left
across the image, pink) in the catalytic groove results in the formation of a two-stranded antiparallel b-sheet. Residues forming the catalytic triad (Ser606, His428 and
Asp372) are shown as yellow sticks. (B) Atomic level illustration of the backbone interactions made by SERA4st1 residues at positions P1 (Gln), P2 (Ala), P3 (Thr), P4 (Ile) and
P20 (Asp) with residues in the active site pockets S1 (Ser606 and Ser490), S2 (Lys465), S3 (Ser492), S4 (Gly467) and S0 (Asn603), with these PfSUB1 residues represented as
pale green sticks and the hydrogen bonding pattern shown as dotted lines. The PfSUB1 oxyanion hole partner Asn520, which helps to stabilize the oxyanion generated in the
tetrahedral transition state, is also pictured. In addition to the canonical binding, side-chains of SERA4st1 residues at positions P10 (Asp) and P30 (Glu) could potentially
contribute to the substrate–enzyme binding by interacting with the PfSUB1 S2 Lys465 side chain e-amino group. In bacterial family S8 subtilisins, this Lys is replaced by a
conserved Gly. The catalytic Ser is shown in yellow.
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tic of the S2 pocket is that it is small, being delimited by the side-
chain of Lys465 (which is a Gly in most subfamily S8A subtilisins;
see Supplementary Table S1), explaining the strict restriction to
only the small residues Ala or Gly at the P2 position (Supplemen-
tary Fig. S3). The PfSUB1 S1 pocket (orange) is narrower than the
equivalent subtilisin Carlsberg pocket (Fig. 4C) and is characterised
by a cluster of ﬁve polar residues, Ser490, Ser492, Ser517, Ser519
and Ser537. The latter residue corresponds to Gly166 in bacterial
subfamily S8A subtilisins, which lies at the bottom of the S1 pocket
and has been extensively mutated to demonstrate its importance
in enzyme substrate preference and catalysis; for example replace-
ment with Asp of Gly166 in the subtilisin BPN0 S1 pocket modiﬁes
its speciﬁcity towards substrates containing P1 Lys (Wells et al.,
1987b). The rim of the PfSUB1 S1 pocket is formed by Asp494 plus
a free cysteine, Cys521, which also increases the polarity of the S1
pocket and may account for the sensitivity of PfSUB1 to para-
hydroxymercuribenzoate (pHMB) and other sulfhydryl-reactive
compounds (Withers-Martinez et al., 2002). In most bacterial sub-
tilisins, the residue at this position (the structurally equivalent res-
idue in subtilisin Carlsberg is Ser156; Supplementary Table S1) also
dramatically inﬂuences P1 preference (e.g. Wells et al., 1987a,b).
On the PfSUB1 S0 sub-site, the top rim of the S0 pocket is formedby Phe575, which is highly conserved in subfamily S8A bacterial
subtilisins. Two of the three other residues (Arg600, Lys601 and
Asn603) making up the PfSUB1 S0 pocket are basic. Together with
the inﬂuence of Lys465, this results in an overall highly basic char-
acter to the S0 surface.
3.3. Molecular dynamics simulation suggests that both prime and
non-prime side interactions are involved in substrate recognition by
PfSUB1
To seek further insights into the binding determinants of the
SERA4st1 substrate, we performed an unrestrained MD simulation
of the PfSUB1–SERA4st1 complex in explicit solvent. Determining
the RMSF of backbone atoms of the bound peptide revealed that
pronounced conformational changes occur at the P20–P50 prime
side residues, whereas the remaining part of the peptide backbone
remain essentially unchanged (Fig. 5A and B). The restricted ﬂuctu-
ation of the P5–P10 residues is in agreement with strong backbone-
backbone hydrogen bonds being formed between P20–P4 and the
PfSUB1 binding site (Fig. 3). Over the course of the 50 ns of simu-
lation time, very stable canonical hydrogen bonds (with an occu-
pancy of at least 80%, indicated in red in Fig. 5C) are formed
between the amino group of P20 and the carbonyl group of
Fig. 4. Architecture of the Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) active site. (A) Molecular surface representation of PfSUB1 (grey), in complex with
SERA4st1 (yellow carbon coloured stick). The ﬁve substrate binding pockets comprise S1 (orange), S2 (slate blue), S3 (indigo blue), S4 (pink) and S0 (turquoise). (B) Close-up
view of the active site (delimited in (A) by the white dotted frame) using a see-through PfSUB1 molecular surface to reveal residues that form the substrate-binding pockets,
colour-coded as in (A). These are: in the S1 pocket: Ser517, Ser519, Ser490, Ser492, Asp494, Ser537 and Cys521; in the S2 pocket: Ser373, Asn426, Leu 461 and Lys465; in the
S3 pocket: Leu466 and Ser492; in the S4 pocket: Leu469, Met472, Phe491, Phe493, Glu 495 and Phe500; and in the S0 pocket: Phe575, Arg600, Lys601 and Asn603. Ser492 is
seen to belong to two pockets; its side chain is part of S1 and its backbone S3. This position corresponds to a Gly in several bacterial subtilisins. As seen in this view, the S1
pocket is polar, the S2 pocket is small due to the Lys465 side chain conformation, the S3 pocket faces the solvent, the S4 pocket is non-polar (with the exception of Glu495 at
the rim of the pocket), and the S0 pocket is mainly basic. (C) For comparison, molecular surface of the bacterial subtilisin DY Carlsberg (1BH6) in grey, shown with bound N-
benzyloxycarbonyl-Ala-Pro-Phe-chloromethyl ketone (pink sticks), showing the S1 and S4 pockets that dictate speciﬁcity. Both pockets are solvent-accessible, large and
predominantly hydrophobic, explaining the broad speciﬁcity of this enzyme and its preference for large non-polar residues at the P1 and P4 positions.
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bonyl group of P4 with the corresponding backbone groups of
Gly467. Further canonical hydrogen bonds (with an occupancy of
at least 40%, indicated in orange or green in Fig. 5C) are formed be-
tween the carbonyl group of P1 and Thr605 and Ser606, respec-
tively, between the amino group of P1 and Ser490, and between
the amino group of P2 and Lys465, respectively. In addition, stabi-
lizing hydrogen bond interactions are formed between the side-
chain carboxylate group of P1 and the backbone amide group of
Asn520 in the S1 pocket, between the side-chain keto group of
P10 and the side chain e-amino group of Lys465 in the S2 pocket,
and between the side-chain hydroxyl group of P30 and the side-
chain guanidinium group of Arg600.
All of these observations conﬁrm the canonical binding mode
suggested by our initial modelled peptide–PfSUB1 complex struc-ture. In addition, they suggest that stabilizing prime side interac-
tions, in particular involving the P10 and P30 residues, may also
play important roles in substrate binding and correct positioning
of the cleavage site. This is of particular interest as it could explain
the observed preference of PfSUB1 for substrates possessing acidic
or hydroxyl-containing residues on their P0 side.
3.4. Cleavage of PfSUB1 substrates requires interactions with prime
side residues
Our earlier alanine scanning studies (Koussis et al., 2009) using
a panel of derivatives of a quenched ﬂuorogenic substrate based on
the internal PfSUB1 autocatalytic cleavage site 213LVSAD ; NI-
DIS222, showed that replacement with Ala of the P30 Asp had a sig-
niﬁcant effect on cleavage efﬁciency, reducing the kcat/Km by 50%.
Fig. 5. Molecular Dynamics simulation of the Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) structure in complex with SERA4st1. (A) Binding mode of SERA4st1
extracted after 40 ns from the MD simulation. Hydrogen bond interactions between the peptide (yellow carbon coloured stick) and PfSUB1 are indicated by dashed lines. (B)
Root-mean square ﬂuctuations (RMSF) about the mean position of the peptide backbone atoms. For RMSF calculation, overall translational and rotational motions were
removed with respect to the Ca atoms of the PfSUB1 structure. (C) Scheme of hydrogen bonds formed during the MD simulation between PfSUB1 and peptide backbone and
side-chain atoms. The peptide orientation is shown from N- to C-terminus left-to-right, and thus is opposite to the orientation shown in (A). Very strong hydrogen bonds
(occupancy of 80–100%) are boxed in red, strong hydrogen bonds (occupancy of 60–80%) are in orange, and weaker hydrogen bonds (occupancy of 40–60%) are shown in
green. Occupancy values were obtained over the course of the entire 50 ns of simulation time. Repeating the analysis for the ﬁrst and second half of the trajectory resulted in
the same hydrogen bond pattern.
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containing side-chains in the prime side positions of physiological
PfSUB1 substrates (Supplementary Fig. S3), and the MD data which
suggest stabilising interactions between PfSUB1 residues and the
P10 and P30 residues, we wished to further address the possibility
that prime side interactions might play an unusually important
role in substrate recognition by PfSUB1 and its orthologues by
examining the activity of PfSUB1 against peptide substrates de-
pleted of or entirely lacking prime side residues. Peptide Ac-EI-
KAET, based on the SERA5 site 1 peptide Ac-EIKAE ; TEDDD
previously shown to be an excellent PfSUB1 substrate (Yeoh
et al., 2007), was examined for its capacity to be cleaved by rPf-
SUB1cat. No hydrolysis of Ac-EIKAET was evident even following
prolonged incubations (data not shown), indicating that a single
prime side residue is insufﬁcient for efﬁcient interaction with
PfSUB1. Many commonly-used ﬂuorogenic protease substrates
are based on peptidyl derivatives of 7-amino-4-methylcoumarin
(AMC), in which cleavage of the peptide–AMC anilide bond results
in release of the free ﬂuorophore. These substrates are widely used
for activity assays with subtilisins and other proteases (e.g. Backes
et al., 2000; Wildeboer et al., 2009), but their utility depends on the
enzymes under examination not having essential prime side
requirements. Peptide Ac-KITAQ-AMC, based on the non-prime
side P5–P1 residues of the SERA4st1 substrate used for the model-ling experiments, was next examined for its capacity to act as a
PfSUB1 substrate. Again, this was completely resistant to hydroly-
sis (not shown). Although alternative possibilities cannot be ruled
out – such as steric hindrance imposed by the bulky AMC moiety
perturbing interactions with both sides of the scissile bond – these
ﬁndings are consistent with the MD data in suggesting that prime
side interactions are important for substrate recognition by
PfSUB1.
In a third approach to investigating the role of prime side inter-
actions in PfSUB1–substrate recognition, we produced a modiﬁed
form of the SERA4st1 peptide substrate (called SERA4st1-ADA) in
which both the P10 and P30 residues were replaced by Ala. Based
on our MD data, these substitutions would be predicted to abolish
potentially important stabilizing interactions with the S0 surface
of the enzyme. To compare cleavage efﬁciencies of SERA4st1 and
SERA4st1-ADA, we used a previously-described method in which
an equimolar mixture of the two peptides was supplemented with
rPfSUB1cat and the rates of peptide hydrolysis established by RP-
HPLC analysis of the resulting digestion products (Child et al.,
2010). Under such conditions, because the peptides effectively act
as competing substrates, their relative initial rates of hydrolysis
are solely a function of the ability of PfSUB1 to discriminate be-
tween them, and so are directly proportional to their relative kcat/
Km values, irrespective of their concentration (Cornish-Bowden,
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ADA is an extremely poor substrate for PfSUB1, exhibiting an initial
cleavage rate at least 80-fold lower than that of the parental SER-
A4st1 peptide (based on comparison of areas under substrate peaks
when digestion of SERA4st1 had proceeded 620%). Importantly,
although prolonged digestion of SERA4st1-ADA alone resulted in
only limited cleavage, this took place predominantly at the ex-
pected Gln-Ala bond, as shown by the appearance in the RP-HPLC
elution proﬁle of the same N-terminal cleavage product (Ac-KITAQ)
as seen with SERA4st1 (Supplementary Fig. S4). These results show
unambiguously that prime side residues play a critical role in sub-
strate hydrolysis by PfSUB1.Fig. 6. Prime side residues play a critical role in substrate recognition by
Plasmodium falciparum subtilisin-like protease 1 (PfSUB1). Reversed-phase-HPLC
chromatograms showing a time-course of digestion by rPfSUB1cat of an equimolar
mixture of the N-acetylated decapeptide SERA4st1 (Ac-KITAQ ; DDEES; based on a
PfSUB1 processing site in SERA4) plus peptide SERA4st1-ADA, in which the P10 and
P30 residues of SERA4st are replaced with Ala. The top chromatogram shows the
elution proﬁle of the undigested mixture, whilst the lower chromatograms are of
samples taken over the course of a 120 min digestion. Identities of substrate peaks
are indicated, as is the N-terminal product of SERA4st1 cleavage (Ac-KITAQ)
(determined by electrospray mass spectrometry). As described previously (Yeoh
et al., 2007) the highly polar C-terminal cleavage product of SERA4st1 digestion is
not retained by the Reversed-phase-HPLC column but elutes in the column ﬂow-
though. Note that for determination of relative initial rates of cleavage, cleavage
rates were compared when the faster-cleaved peptide (SERA4st1) was digested by
620%. For clarity, in this experiment digestion was allowed to proceed much
further. As can be seen, by 120 min, the SERA4st1 peak intensity was reduced by
84.6%, whilst the SERA4st1-ADA peak was reduced by only 1%.3.5. Homology modelling and recombinant expression of other
Plasmodium SUB1 orthologues deﬁnes conserved and species-speciﬁc
characteristics
To investigate potentially informative structural similarities
and differences between the active site architectures of SUB1
orthologues from other clinically and experimentally important
malarial species, we built homology models of the catalytic do-
mains of PkSUB1, PvSUB1 and PbSUB1, for comparison with the
PfSUB1 model. This revealed (Fig. 7A) that the active sites of
PvSUB1 and PkSUB1 are identical to each other and very similar
to that of PfSUB1, the only important difference being the replace-
ment of Ser537 at the base of the PfSUB1 S1 pocket with Ala in
PvSUB1 and PkSUB1 (see also Supplementary Table S1). This would
be predicted to result in a slightly less polar S1 pocket in these en-
zymes. In addition, Glu463 below the PfSUB1 S2 pocket is replaced
by a Gln residue in PvSUB1 and PkSUB1, but this lies some distance
from the substrate interactions so it is anticipated to have little if
any effect on the conformation of the S2 pocket. In contrast, an
examination of the modelled PbSUB1 active site indicated more
structural divergence, with a total of six substitutions relative to
PfSUB1. Notable amongst these is Ile386 at the base of the S4 pock-
et, which replaces a Met residue in PfSUB1, PvSUB1 and PkSUB1,
and results in a slight increase in the size and hydrophobicity of
the PbSUB1 S4 pocket. The PbSUB1 S0 sub-site composition is even
more divergent, with Ser516 replacing Asn603 in PfSUB1, and
Met513 and Glu514 replacing, respectively, Arg600 and Lys601
in PfSUB1. Combined, these substitutions are predicted to provide
PbSUB1 with a less basic S0 surface than the other three ortho-
logues, evident from a comparison of the electrostatic surface
views (Supplementary Fig. S5). In summary, modelling of the
SUB1 orthologues suggests that PvSUB1 and PkSUB1 likely share
very similar substrate speciﬁcity with PfSUB1, whilst some differ-
ences in the speciﬁcity of PbSUB1 at the P4 and P0 positions are
likely.
To test this interpretation, we expressed recombinant PvSUB1,
PkSUB1 and PbSUB1 in the same baculovirus expression system
previously used for PfSUB1. As expected, examination of the puri-
ﬁed expressed products suggested that, similar to PfSUB1, each
was secreted in a complex with its cognate PD (Fig. 7B), as indi-
cated by the presence of a 25–30 kDa species observable on
Coomassie-stained gels of the puriﬁed proteins in addition to the
higher-migrating product of around the expected mass for the cat-
alytic domain-containing protein product. This was most evident
in the case of rPvSUB1, where the putative PD and catalytic domain
species were sufﬁciently highly-expressed to allow analysis of the
latter by N-terminal sequencing. This identiﬁed the N-terminal se-
quence Asp-Val-Ser-Leu-Ala in the ﬁrst ﬁve cycles of Edman degra-
dation, conﬁrming its identity and consistent with autocatalytic
cleavage at the predicted internal processing site (Supplementary
Fig. S1). Preliminary experiments showed that the puriﬁed prod-
ucts exhibited low protease activity in their PD-bound form, so
all were subjected to limited digestion with chymotrypsin as de-
scribed above for PfSUB1; this successfully resulted in each case
in conversion to a lower molecular mass form and complete or par-
tial removal of the PD species as determined by Coomassie-blue
staining (not shown). The resulting ‘activated’ protease prepara-
tions were then examined for their capacity to cleave the PfSUB1
substrate SERA4st1F6R-12 (a ﬂuorogenic substrate based on P5–
P50 of the SERA4st1 cleavage site), as well as SERA5st1F-6R and
SERA5st2F-6R, ﬂuorogenic substrates based on P4–P40 of the SERA5
site 1 and site 2 processing sites, IKAE ; TEDD and IFGQ ; DTAG
(Yeoh et al., 2007). All three enzymes cleaved these substrates at
the same Gln-Asp, Glu-Thr and Gln-Asp bonds, respectively, that
are cleaved by PfSUB1, as determined from the characteristic elu-
tion proﬁles of the digestion products on RP-HPLC (not shown).
Fig. 7. Homology modelling and recombinant expression reveals similarities and differences between Plasmodium subtilisin-like protease 1 (SUB1) orthologues. (A)
Molecular surface representation of homology models of the Plasmodium vivax (Pv)SUB1, Plasmodium knowlesi (Pk)SUB1 and Plasmodium berghei (Pb)SUB1 catalytic domains.
Coloured residues (blue for PvSUB1, green for PkSUB1, red for PbSUB1) indicate positions that are different from structurally equivalent residues in PfSUB1, whereas identical
residues are shown in grey. The catalytic Ser is shown in yellow. White dashed frames delimitate the active site grooves, and the zoomed views below show the modelled
binding mode of SERA4st1 (KITAQ ; DDEES). PvSUB1 and PkSUB1 are almost identical to PfSUB1 in the active site region, with the only two substitutions being Ala481 and
Gln407 in PvSUB1, and Ala490 and Gln416 in PkSUB1. In contrast, PbSUB1 diverges signiﬁcantly, with six substitutions (His340, Lys378, Ile386, Met513, Glu514 and Ser516),
indicating likely differences in the speciﬁcity of this enzyme at the P4 and P0 positions. (B) Recombinant expression of SUB1 orthologues. Proteins were expressed using
baculovirus-infected insect cells and puriﬁed as described in Section 2.1. Positions of migration of the protease domain and the prodomain species resulting from cleavage
during maturation are indicated. The left-hand track on each gel contains molecular mass standards of the indicated sizes. Predicted molecular masses of the protease
domains resulting from cleavage at the expected autocatalytic processing site (Supplementary Fig. S1) are: PvSUB1, 48,082 Da; PkSUB1, 49,072 Da; and PbSUB1, 44,868 Da.
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rately determine concentrations of the active forms of the different
recombinant enzymes, and thus could not calculate kcat values for
cleavage of the substrates. However, we noticed that the activity of
rPbSUB1 against all three substrates was consistently at least 10-
fold lower than expected from concentrations of this protein as
determined by Coomassie blue-stained gels (not shown). In the
light of this and the modelling data suggesting that PbSUB1 maypossess divergent substrate speciﬁcity, we decided to explore this
in more detail.
An examination of the predicted internal processing site within
PbSUB1 (Supplementary Fig. S1) shows that, unlike PfSUB1,
PvSUB1 or PkSUB1, the PbSUB1 cleavage site does not contain an
acidic residue in either the P10 or P30 positions, instead possessing
P10 Ser. A P10 Ser is found in some known PfSUB1 and predicted
PvSUB1 and PkSUB1 substrates, but is strikingly conserved in most
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P. berghei MSP1 (PbMSP1) (Jennings et al., 1998) and many of the
predicted cleavage sites in P. berghei SERA family members, includ-
ing PbSERA3, thought to be essential in P. berghei blood-stages
(Putrianti et al., 2010; Arisue et al., 2011) (Supplementary Table
S2). To conﬁrm that PbSUB1 can cleave substrates based on some
of these sites, unlabelled N-acetylated decapeptides corresponding
to three of the established cleavage sites within PbMSP1, as well as
a predicted cleavage site within PbSERA3 (the P. berghei orthologue
of P. falciparum SERA6) were examined for their capacity to be cor-
rectly cleaved by rPbSUB1. As shown in Supplementary Table S3,
peptides Ac-TTSGQ ; SSTEP, Ac-VVTGE ; SEETS, Ac-TTRAE ; SEEDI
and Ac-DVSGQ ; SENHQ were all correctly cleaved by rPbSUB1 at
the expected positions, as shown by RP-HPLC examination of
digestion products.
To address the potential importance of the P10 Ser residue in
substrate cleavage by PbSUB1, we explored whether a PfSUB1 sub-
strate that is a poor substrate for PbSUB1 could be converted to a
better PbSUB1 substrate by substitution of the P10 residue with
Ser. We produced the ﬂuorogenic substrate SERA4st1F-6R, which
is the peptide Ac-CITAQDDEEC (corresponding to P4–P40 of the
SERA4st1 cleavage site) labelled on both terminal cysteine side-
chains with 6-IATR. In parallel, we generated the derivative
SERA4st1F-6R-S, which contains a Ser substitution of the P10
(Asp) residue in SERA4st1F-6R. Cleavage of SERA4st1F-6R by
rPfSUB1cat resulted in the expected ﬂorescence increase, with
conversion of the substrate to just two ﬂuorescent products corre-
sponding to cleavage at the expected Gln-Asp bond, as determined
by RP-HPLC and mass-spectrometry (data not shown). Fig. 8 shows
a kinetic analysis comparing cleavage of SERA4st1F-6R and SER-
A4st1F-6R-S by rPfSUB1cat and rPbSUB1cat. At a standard concen-
tration of both substrates (0.1 lM) which is well below their Km
and therefore corresponding to conditions where the rate of cleav-
age is directly proportional to kcat/Km, it can be seen that whereas
rPfSUB1cat cleaves both substrates equally well, SERA4st1F-6R-S is
a much better substrate for rPbSUB1cat than SERA4st1F-6R. These
results conﬁrm that – as in the case of PfSUB1 – prime side resides
do indeed contribute to substrate recognition by PbSUB1, and sug-
gest that PbSUB1 prefers P10 Ser to Asp, whereas PfSUB1 does not
discriminate between them under these conditions. The observa-Fig. 8. Plasmodium berghei subtilisin-like protease 1 (PbSUB1) prefers a P10 Ser to
Asp. Typical progress curves showing cleavage of ﬂuorogenic substrate SERA4st1F-
6R (6-iodoacetamido tetramethylrhodamine (6-IATR)-labelled Ac-CITAQDDEEC) by
recombinant Plasmodium falciparum SUB1 catalytic domain (rPfSUB1cat; closed
circles) and rPbSUB1cat (closed triangles), and cleavage of SERA4st1F-6R-S (6-IATR-
labelled Ac-CITAQSDEEC) by rPfSUB1cat (closed squares) and rPbSUB1cat (closed
diamonds). Substitution of the P10 Asp in SERA4st1F-6R with a Ser in SERA4st1F-6R-
S results in a 5.8-fold increase in initial hydrolysis rates by rPbSUB1cat, but has no
signiﬁcant effect on cleavage by rPfSUB1cat. Both substrates were used at 0.1 lM
ﬁnal concentration in the digestion reactions.tion that authentic PbSUB1 cleavage sites in at least two essential
proteins possess P10 Ser suggests that the enzyme has co-evolved
with its cognate endogenous substrates in order to maintain opti-
mal catalytic activity.3.6. Peptidyl alpha-ketoamides based on a PfSUB1 substrate inhibit
SUB1 from all three major human pathogens
Our evidence that PfSUB1, PvSUB1 and PkSUB1 share similar
substrate speciﬁcity suggested that it might be possible to design
substrate-based compounds that inhibit all three proteases. Pep-
tide alpha-ketoamides are well documented as mechanism-based
covalent inhibitors of serine proteases, typically binding in a sub-
strate-like manner and forming reversible covalent bonds with
the hydroxyl side-chain of the catalytic Ser, so to test that notion
we synthesised two N-acetylated peptidyl alpha-ketoamides based
on the structure of the best known PfSUB1 substrate, SERA4st1.
Compound KS-182 (Fig. 9A) was ﬁrst examined for its capacity to
inhibit rPfSUB1cat activity. As shown in Fig. 9B, addition of KS-
182 (ﬁnal concentration 100 lM) to a digestion reaction resulted
in rapid and essentially complete inhibition of substrate hydroly-
sis, indicating that KS-182 is a fast-binding inhibitor of PfSUB1.
Further similar progress-curve experiments (Fig. 9C) allowed us
to calculate an apparent tight binding inhibition constant (Ki(app))
of 7.3 lM for inhibition of rPfSUB1cat. This was conﬁrmed in addi-
tional dose–response experiments (Fig. 9D) which showed that the
IC50 for steady-state inhibition of rPfSUB1cat by KS-182 is 6 lM.
Importantly, KS-182 also inhibited rPvSUB1 and rPkSUB1 with IC50
values of 12 lM and 6 lM, respectively. In accord with the dis-
tinct substrate requirements of PbSUB1, the IC50 of KS-182 against
PbSUB1 was much higher, at P100 lM (not shown). As a control
compound for these experiments we produced a derivative of KS-
182 called KS-378, in which the ketoamide function is replaced by
an amino-alcohol group (Fig. 9A); this is expected to lack the
capacity to form a covalent adduct with the enzyme catalytic Ser.
KS-378 showed no inhibitory activity against any of the SUB1
orthologues at concentrations up to 100 lM (data not shown).
Encouraged by our results with KS-182, we designed an ana-
logue possessing an extended terminal structure designed to mi-
mic the prime side interactions predicted by our modelling and
experimental data to be important for substrate recognition by
PfSUB1. Compound KS-644 (Fig. 9A) possesses a carboxyl-contain-
ing moiety on the prime side of the alpha-ketoamide functionality.
Like KS-182, this compound also proved to be a fast-binding inhib-
itor of PfSUB1 but exhibited signiﬁcantly increased potency, with a
calculated Ki(app) of 0.7 lM (Fig. 9E). This enhanced potency was
conﬁrmed by dose–response experiments which showed an IC50
against PfSUB1 and PkSUB1 of 1 lM, and an IC50 against PvSUB1
of2 lM (Fig. 9F). Importantly, neither KS-378 nor KS-466 showed
any activity against bovine trypsin at concentrations up to 100 lM
(data not shown). These results conﬁrm that selective inhibitors
based on PfSUB1 substrates can also inhibit both PvSUB1 and
PkSUB1, raising the possibility of developing drug-like SUB1-inhib-
itors that target all three major human malaria pathogens.4. Discussion
We have combined detailed modelling of the SUB1 active site
with experimental analysis of substrate speciﬁcity and inhibitor
sensitivity. Our ﬁndings allow us to reach several important con-
clusions with implications for both improving predictions of
SUB1 substrates, and for development of inhibitors with broad po-
tential as antimalarial agents.
We ﬁrst demonstrated experimentally that rPfSUB1 can be pro-
teolytically converted to a ‘core’ domain that possesses all of the
Fig. 9. Peptidyl alpha-ketoamides based on a Plasmodium falciparum subtilisin-like protease 1 (PfSUB1) substrate are micromolar inhibitors of PfSUB1, Plasmodium vivax SUB1
(PvSUB1) and Plasmodium knowlesi SUB1 (PkSUB1). (A) Structures of the alpha-ketoamide KS-182, the corresponding aminoalcohol KS-378, and the extended KS-182
derivative KS-466. (B) Typical progress curve showing the proﬁle of ﬂuorescence increase with time produced by cleavage of substrate SERA4st1F-6R12 (0.1 lM) by
recombinant P. falciparum SUB1 catalytic domain (rPfSUB1cat; 1 U/ml). The arrow indicates the point at which the reactions were supplemented with KS-182 (100 lM ﬁnal,
added from a 10 mM stock solution in DMSO; closed triangles), 1 mM para-hydroxymercuribenzoate (positive control inhibitor, closed circles), or 1% v/v DMSO (vehicle only
control, closed squares). (C) and (E) Determination of Ki(app) values for inhibition of rPfSUB1cat by KS-182 and KS-466. Progress curves showing the effects of adding different
concentrations of the peptidyl alpha-ketoamides to an ongoing digestion are as in A. The point of compound addition is indicated by an arrow in each plot. In all cases,
compounds were diluted 1:100 into the digestion reactions, from stock dilutions in DMSO. The ﬁnal DMSO concentration in each reaction was therefore invariant at 1% (v/v).
Values of Ki(app) were calculated as described in Section 2.3. Since the concentration of substrate SERA4st1F-6R12 used for these experiments (0.1 lM) is well below its km, the
calculated Ki(app) is unlikely to be signiﬁcantly different from the Ki (Nicklin and Barrett, 1984). (D and F) Dose–response curves showing the relationship between
concentrations of KS-182 or KS-466, and inhibition of rPfSUB1cat, rPkSUB1cat, and rPvSUB1cat. Calculated IC50 values are 6 lM, 6 lM and 12 lM, respectively, for KS-182, or
1 lm, 1 lM and 2 lM for KS-466. Points are means of triplicate measurements and error bars indicate S.D. values. The horizontal dotted line in each plot indicates 50%
inhibition of protease activity.
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nearly 10-fold increase in proteolytic activity following chymotryp-
sin treatment probably derives primarily from removal of the inhib-
itory PD, which is a 5 nM inhibitor of its cognate enzyme (Jean
et al., 2003). Many subtilisin PDs are highly sensitive to proteolysis
(Siezen and Leunissen, 1997), so it was no surprise to ﬁnd that the
PfSUB1 PD is relatively susceptible to degradation by chymotrypsin.
We have previously reported (Withers-Martinez et al., 2002) that
puriﬁed rPfSUB1 tends to aggregate and adsorb non-speciﬁcally
to glass and other surfaces, making it difﬁcult to manipulate. One
additional advantage of the chymotrypsin digestion procedure is
that the resulting rPfSUB1cat appears homogeneous and fully solu-
ble, lacking the undesirable ‘sticky’ properties of the native recom-
binant protein. This characteristic is currently being exploited in
crystallisation screens aimed at solving its three-dimensional
structure.
Molecular modelling of the PfSUB1 active site groove, as well as
that of its P. vivax, P. knowlesi and P. berghei orthologues, together
with MD analysis, demonstrated several conserved features of the
substrate S1–S4 binding pockets. These include the non-polar nat-
ure of the S4 pocket, the restricted S2 pocket resulting from a con-
served Lys residue (Lys465 in PfSUB1), and the polar nature of the
S1 pocket. Contributing to the latter is a free Cys residue (Cys521 in
PfSUB1) which is conserved in all of the SUB1 orthologues. The
presence of a free Cys close to the active site is not unprecedented
in subtilisins; for example, thermitase, proteinase K and cerevisin
each have a free Cys close to the catalytic His, which is accessible
to mercury compounds. PfSUB1 is potently inhibited by pHMB,
and it seems likely that Cys521 is the target of that compound. It
is possible that this feature could be exploited in the design of
drugs based on active site-directed compounds possessing suitable
alkylating ‘warhead’ functions.
A particularly interesting prediction of our modelling analysis
was the indication that – uniquely for a subfamily S8A subtilisin
as far we are aware – prime side interactions may play important
roles in substrate binding by PfSUB1 and its orthologues. The
highly basic overall nature of the S0 pocket and the presence of
the conserved Lys (Lys465 in PfSUB1), which not only restricts
the size of the S2 pocket but may also form stabilizing salt-bridge
interactions with P10, is completely consistent with the clear pref-
erence of PfSUB1 for acidic or hydroxyl-containing prime side sub-
strate residues. This was experimentally conﬁrmed by
modiﬁcation of the SERA4st1 substrate; simultaneous substitution
with Ala of the P10 and P30 acidic residues resulted in a dramatic
decrease in its susceptibility to cleavage by PfSUB1. Our evidence
that the architecture of the S0 pocket of PvSUB1 and PkSUB1 is
identical to that of PfSUB1 implies a similar prime side preference
for these enzymes, and an examination of predicted SUB1 process-
ing sites in P. knowlesi and P. vivax SERA family members is in ac-
cord with that prediction (Supplementary Table S2 and Arisue
et al., 2011), revealing a similarly strong tendency towards acidic
residues, Ser and Thr in the P10–P40 positions. This clearly increases
conﬁdence that the SERA proteins are indeed substrates for SUB1
in those Plasmodium spp., just as in P. falciparum. The PbSUB1 ac-
tive-site architecture is more divergent, and more work is required
to elucidate the wider implications of this. However, the differ-
ences revealed here between the P10 preference of PbSUB1 and
PfSUB1, together with the observed presence of P10 Ser in likely
important PbSUB1 cleavage sites such as its own putative autocat-
alytic processing site, and cleavage sites in the essential P. berghei
proteins PbMSP1 and PbSERA3 (peptides based on some of which
were shown here to be cleaved as predicted by rPbSUB1), implies
co-evolution of protease and substrates following divergence of
these Plasmodium spp. from their common ancestor. In the light
of our ﬁndings here, it may be signiﬁcant that attempts to replace
the P. berghei pbsub1 gene with the pfsub1 gene by targeted homol-ogous recombination have consistently failed (Tewari, Yeoh, Billker
and Blackman, unpublished data), consistent with the notion that
the two orthologues are not functionally interchangeable due to
their distinct substrate preferences. It could be imagined that a
defect in proteolytic processing of even a single critical P. berghei
substrate would be sufﬁcient to render transgenic parasites har-
bouring such an allelic replacement non-viable.
It is important to make an additional point regarding SUB1 sub-
strate speciﬁcity. Previous work on processing of both MSP1 and
SERA5 by PfSUB1 has shown that cleavage at the various sites
within these large molecules takes place in an ordered manner.
Thus, in SERA5 cleavage occurs at site 1 before site 2 (Yeoh et al.,
2007), whereas in MSP1 cleavage at the most C-terminal PfSUB1
site occurs more slowly than at the other positions (Child et al.,
2010). Since SUB1 is a processing protease (rather than purely a
degradative enzyme), it is plausible that there may be a biological
role for some authentic substrate sequences being cleaved better
(i.e. more rapidly) than others. In the light of this, a simple view
of substrate preference based on allocating equal ‘weight’ to an
assemblage of known target sequences (as in Supplementary
Fig. S3) may be misleading, as it does not take into account the
likelihood that certain sequences may have evolved to be much
better substrates than others. In the light of our ﬁndings here
regarding the role of prime side interactions, it may therefore be
no coincidence that the best PfSUB1 substrate identiﬁed to date
based on a physiological cleavage site – SERA4st1 – contains exclu-
sively acidic residues at the P10–P40 positions. In contrast the slow-
est-cleaved authentic substrates identiﬁed (Child et al., 2010),
those based on the 38/42 processing site in two allelic forms of
MSP1, are relatively deﬁcient in acidic or hydroxyl-containing
prime side residues (their sequences are VVTGE ; AISVT and
VVTGE ; AVTPS). Collectively, our data suggest a rational basis for
these differences in substrate preference, and provide information
that will be invaluable in searching for new SUB1 target sequences.
A valuable tool in understanding the function of SUB1-mediated
processing is mutagenesis of established cleavage sites, and our
ﬁndings also suggest that appropriate substitution of prime-site
residues may aid in blocking cleavage.
It is interesting to consider the prime side requirements of SUB1
in the light of its maturation mechanism. In those subfamily S8A
and S8B subtilases where proteolytic maturation has been well
studied, protease activation follows a single cleavage at the PD-
mature domain boundary. This results either in PD degradation,
or a second precise cleavage within the PD itself which results in
its removal. In the case of subtilisin BPN0, X-ray crystallographic
studies have shown that, following cleavage, a large conformational
shift occurs inwhich the segment corresponding to sequence on the
prime side of the scissile bond (i.e. the N-terminus of the nascent
mature protease domain) moves 25 Å from the active site groove
to leave it unobscured (Gallagher et al., 1995; Jain et al., 1998).
Activation of furin is a two-step process; initial cleavage takes place
at Arg107 but this is not sufﬁcient for furin activation, since PD re-
moval is only achieved following further furin-mediated cleavage at
a second site (Arg75) within the PD, following acidiﬁcation (Ander-
son et al., 1997, 2002). By contrast to both these mechanisms, in
PfSUB1 the second cleavage takes place downstream of the ﬁrst
cleavage – that is, within the C-terminal product of the primary
cleavage event (Sajid et al., 2000) – suggesting that the prime side
segment may initially remain in the active site groove, blocking ac-
cess of exogenous substrate to the active site until the second cleav-
age event takes place. The prime side interactions observed here
may aid in stabilising this intermediate complex (Supplementary
Fig. S6). Further work is required to explore this model, but it
may represent a novel maturation process for subtilisins.
Our evidence that the human malaria pathogen SUB1 ortho-
logues share very similar active site structures led us to explore
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all three proteases. Peptide-based inhibitors generally have poor
bioavailability and pharmacokinetics, but have proven to be excel-
lent starting points for the development of substrate-based inhib-
itors (e.g. Chen and Njoroge, 2010). Our initial identiﬁcation here of
KS-182 as an inhibitor of PfSUB1, PvSUB1 and PkSUB1 provided
proof-of-principle that the similar active-site architecture of these
enzymes should allow the development of suitable broad-spec-
trum non-peptidic inhibitors. Alpha-ketoamides have the impor-
tant advantage over several other electrophilic pharmacophores
that synthetic elaboration on both sides of the alpha-ketoamide
function is possible. A good recent example of how this character-
istic has been exploited is in the production of selective inhibitors
of the Hepatitis C virus (HCV) NS3 protease where, due to the shal-
low substrate binding groove of this unusual serine protease, it was
necessary to develop compounds that make extended interactions
on both prime and non-prime sides of the catalytic Ser. Two non-
peptidic alpha-ketoamides, Boceprevir and Teleprevir (VX-950),
were recently licensed by the FDA for clinical use to treat HCV
infection (Kwong et al., 2011; Rizza et al., 2011). These were devel-
oped from early 11 residue-long (undecapeptide) peptidyl alpha-
ketoamides extending from P6–P50, demonstrating the power of
a substrate-based approach. KS-182 lacks prime side components,
so in view of our evidence for the importance of prime side inter-
actions in substrate binding, we produced derivative KS-466 which
possesses a prime side carboxyl moiety designed to mimic the
acidic residues important for efﬁcient recognition of substrate
SERA4st1. The substantially increased potency of this compound
compared with KS-182 supports our model. In preliminary exper-
iments, we have found that neither KS-182 nor KS-466 show activ-
ity against the parasite at concentrations up to 100 lM, but this is
unsurprising as both compounds likely lack good membrane-per-
meability properties due to their charged nature. Ongoing work
is aimed at modifying these compounds to reduce their mass and
peptidic nature, whilst enhancing membrane permeability. At
present, we have no plausible explanation for the 2-fold higher
IC50 values obtained for both KS-182 and KS-466 against PvSUB1
compared with PfSUB1 and PkSUB1, given our evidence that the
active-sites of PvSUB1 and PkSUB1 are identical.
What is the potential of SUB1 inhibitors as future antimalarial
drugs? There is no obvious human homologue of Plasmodium
SUB1, the structurally most closely related human enzyme being
tripeptidyl-peptidase II (TPP-II; MEROPS ID S08.090), an exopepti-
dase which releases tripeptides from the N-terminus of peptides,
and which has a substrate speciﬁcity quite unrelated to that of
SUB1 (Rockel et al., 2012). Human lysosomal tripeptidyl-peptidase
I (MEROPS ID S53.003) is the only mammalian member of the S53
sedolisin family, so is structurally distinct from SUB1, with a dis-
tinct substrate speciﬁcity (Tian et al., 2006). Finally, furin and the
eight related proprotein convertases belong to the distinct S8B
subtilase subfamily; they are therefore also structurally distinct
in a number of important ways and exhibit a very different sub-
strate speciﬁcity, centred around a dibasic recognition motif at
the P2–P1 positions (see Seidah, 2011, for a recent review). We
therefore believe that the risk of off-target effects from the
in vivo use of appropriately potent SUB1 inhibitors is small. Inhib-
itors of SUB1 could form a novel and widely applicable addition to
the current dwindling armoury of antimalarial agents.
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